New Report sheds light on the Type 1 diabetes - Pipeline Review, H1 2016

Type 1 diabetes (Juvenile Diabetes) - Pipeline Review, H1 2016 is a new market research publication announced by Reportstack. This report provides an overview of the Type 1 Diabetes (Juvenile Diabetes) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Type 1 Diabetes (Juvenile Diabetes), complete with analysis by stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Type 1 Diabetes (Juvenile Diabetes) and features dormant and discontinued projects.

Complete report available @ Type 1 diabetes (Juvenile Diabetes) - Pipeline Review, H1 2016

This report is built using data and information sourced from a proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. The profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape of Type 1 Diabetes (Juvenile Diabetes)
- The report reviews pipeline therapeutics for Type 1 Diabetes (Juvenile Diabetes) by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report reviews key players involved Type 1 Diabetes (Juvenile Diabetes) therapeutics and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Type 1 Diabetes (Juvenile Diabetes)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Type 1 Diabetes (Juvenile Diabetes)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies Mentioned

AbGenomics International, Inc. Adocia AiCuris GmbH & Co. KG Alteogen Inc. Amarantus Bioscience Holdings, Inc. Ambrx, Inc. AntriaBio, Inc. Aphios Corporation APT Therapeutics, Inc. Araim Pharmaceuticals, Inc. Argos Therapeutics, Inc. Artery Therapeutics, Inc. Astellas Pharma Inc. AstraZeneca Plc Athersys, Inc. Axxam SpA Beta-Cell NV Biocon Limited Biodel Inc. Biogenomics Limited BioLineRx, Ltd. BioLingus AG BioTherapeutics Inc. Boehringer Ingelheim GmbH Caladrius Biosciences, Inc. Carlina Technologies SAS Cellectis S.A. Compugen Ltd. Daewoong Pharmaceutical Co., Ltd. Dance Biopharm Inc. Diabetology (Products) Ltd DiaMedica Inc. Diamyd Medical AB Diasome Pharmaceuticals, Inc. Dompe Farmaceutici S.p.A. Effimune S.A. Eli Lilly and Company enGene, Inc Ensol Biosciences Inc. EpiVax, Inc. Evotec AG F. Hoffmann-La Roche Ltd. Fate Therapeutics, Inc. Generex Biotechnology Corporation GeNeuro SA Geropharm Gilead Sciences, Inc. GlaxoSmithKline Plc Grifols, S.A. Heptares Therapeutics Limited Iltoo Pharma Innopharmax Inc. IntelliCell BioSciences Inc. Intrexon Corporation Islet Sciences, Inc. Johnson & Johnson Kadimastem Ltd. Kamada Ltd. Kasiak Research Private Limited Kineta, Inc. Kissei Pharmaceutical Co., Ltd. Lexicon Pharmaceuticals, Inc. Ligand Pharmaceuticals, Inc. Lonestar Heart, Inc. MacroGenics, Inc. Medestea Research & Production S.p.A. MedImmune, LLC Merck & Co., Inc. Meridigen Biotech Co., Ltd. MidaSol Therapeutics LP Mitsubishi Tanabe Pharma Corporation NOD Pharmaceuticals, Inc. Novo Nordisk A/S Noxxon Pharma AG Oramed Pharmaceuticals, Inc. Orgenesis, Inc. Paras Biopharmaceuticals Finland Oy Parvus Therapeutics, Inc. Pathfinder Cell Therapy, Inc. Pfizer Inc. PharmaCyte Biotech, Inc. PharmaIN Corporation Progen Pharmaceuticals Limited Prometheon Pharma, LLC Purzer Pharmaceutical Co., Ltd. RedHill Biopharma Ltd. REGiMMUNE Corporation Sanofi SEKRIS Biomedical, Inc. Selecta Biosciences, Inc. Sevion Therapeutics, Inc. Strongbridge Biopharma plc Therapix Biosciences Ltd Thermalin Diabetes, LLC Toleranzia AB Transgene Biotek Limited UCB S.A. Uni-Bio Science Group Ltd. United Therapeutics Corporation ViaCyte, Inc. Visionary Pharmaceuticals, Inc. XL-protein GmbH XOMA Corporation Zensun (Shanghai) Sci & Tech Co., Ltd.

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

Reportstack Market Research

###